- Home
- CREV vs APM Comparison
CREV vs APM Comparison
Compare CREV & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- APM
- Stock Information
- Founded
- CREV 2007
- APM 2010
- Country
- CREV Ireland
- APM United Kingdom
- Employees
- CREV N/A
- APM N/A
- Industry
- CREV
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- APM Health Care
- Exchange
- CREV Nasdaq
- APM Nasdaq
- Market Cap
- CREV 5.7M
- APM 6.1M
- IPO Year
- CREV N/A
- APM 2018
- Fundamental
- Price
- CREV $3.10
- APM $0.92
- Analyst Decision
- CREV
- APM
- Analyst Count
- CREV 0
- APM 0
- Target Price
- CREV N/A
- APM N/A
- AVG Volume (30 Days)
- CREV 424.0K
- APM 28.8K
- Earning Date
- CREV 05-14-2025
- APM 06-10-2025
- Dividend Yield
- CREV N/A
- APM N/A
- EPS Growth
- CREV N/A
- APM N/A
- EPS
- CREV N/A
- APM N/A
- Revenue
- CREV $39,261,077.00
- APM N/A
- Revenue This Year
- CREV $40.76
- APM N/A
- Revenue Next Year
- CREV $86.18
- APM N/A
- P/E Ratio
- CREV N/A
- APM N/A
- Revenue Growth
- CREV 41.52
- APM N/A
- 52 Week Low
- CREV $2.00
- APM $0.46
- 52 Week High
- CREV $14.19
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- CREV 48.08
- APM 51.22
- Support Level
- CREV $2.95
- APM $0.83
- Resistance Level
- CREV $3.50
- APM $1.00
- Average True Range (ATR)
- CREV 0.35
- APM 0.08
- MACD
- CREV -0.02
- APM -0.00
- Stochastic Oscillator
- CREV 37.10
- APM 44.24
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.